Intracranial immature teratoma (ImT) is one of the non-germinomatous germ cell tumors, and elevated serum alpha-fetoprotein (AFP) value is a crucial clinical diagnostic indicator of ImT. In this retrospective study conducted among patients diagnosed with intracranial ImT, diagnostic procedures, therapeutic courses, histopathologic diagnosis, and prognosis were reviewed. Among 106 patients with intracranial germ cell tumors, 11 were diagnosed with ImT and treated since 2000. ImT was diagnosed via biopsy or based on mild or moderate serum AFP elevation of 10-500 ng/mL. Complete remission via chemoradiotherapy was achieved in only 2 patients (18%); 5 patients (45%) suffered from growing disease during treatment; and 7 patients required salvage tumor resection. The 10-year progression-free and overall survival rates were 76.2% and 87.5%, respectively. The therapeutic courses of ImT varied. Notably, cases in which treatment was applied considering ImT were highly prone to experience growing disease during treatment.
FujimakiT. Central nervous system germ cell tumors: classification, clinical features, and treatment with a historical overview. J Child Neurol. 2009;24(11):1439–1445.
2.
CalaminusGFrappazDKortmannRD, et al.Outcome of patients with intracranial non-germinomatous germ cell tumors—lessons from the SIOP-CNS-GCT-96 trial. Neuro Oncol.2017;19(12):1661–1672.
3.
SawamuraYIkedaJShiratoHTadaMAbeH. Germ cell tumours of the central nervous system: treatment consideration based on 111 cases and their long-term clinical outcomes. Eur J Cancer. 1998;34(1):104–110.
4.
MatsutaniMSanoKTakakuraK, et al.Primary intracranial germ cell tumors: a clinical analysis of 153 histologically verified cases. J Neurosurg. 1997;86(3):446–455.
5.
MatsutaniM, Japanese Pediatric Brain Tumor Study Group. Combined chemotherapy and radiation therapy for CNS germ cell tumors—the Japanese experience. J Neurooncol. 2001;54(3):311–316.
6.
SugiyamaKAritaKTominagaA, et al.Morphologic features of human chorionic gonadotropin- or alpha-fetoprotein-producing germ cell tumors of the central nervous system: histological heterogeneity and surgical meaning. Brain Tumor Pathol. 2001;18(2):115–122.
7.
TakamiHFukuokaKFukushimaS, et al.Integrated clinical, histopathological, and molecular data analysis of 190 central nervous system germ cell tumors from the iGCT consortium. Neuro Oncol. 2019;21(12):1565–1577.
8.
TakamiHGraffeoCSPerryA, et al.Impact of tumor markers on diagnosis, treatment and prognosis in CNS germ cell tumors: correlations with clinical practice and histopathology. Brain Tumor Pathol. 2023;40(2):124–132.
9.
WuAJinMCVogelH, et al.Treatment course and outcomes of intracranial teratomas in pediatric patients: a retrospective 15-year case series study. Pediatr Neurosurg. 2023;58(6):429–438.
KimCYChoiJWLeeJY, et al.Intracranial growing teratoma syndrome: clinical characteristics and treatment strategy. J Neurooncol. 2011;101(1):109–115.
12.
TsuyuguchiSSugiyamaKKinoshitaY, et al.Primary and recurrent growing teratoma syndrome in central nervous system nongerminomatous germ cell tumors: case series and review of the literature. World Neurosurg. 2020;134:e360–e371.
13.
LogothetisCJSamuelsMLTrindadeAJohnsonDE. The growing teratoma syndrome. Cancer. 1982;50(8):1629–1635.
14.
MichaielGStrotherDGottardoN, et al.Intracranial growing teratoma syndrome (iGTS): an international case series and review of the literature. J Neurooncol. 2020;147(3):721–730.
15.
KanamoriMKumabeTWatanabeM, et al.Indications for salvage surgery during treatment for intracranial germ cell tumors. J Neurooncol. 2018;138(3):601–607.
16.
AoyamaHShiratoHIkedaJFujiedaKMiyasakaKSawamuraY. Induction chemotherapy followed by low-dose involved-field radiotherapy for intracranial germ cell tumors. J Clin Oncol. 2002;20(3):857–865.
17.
MoranaGShawDMacDonaldSM, et al.Imaging response assessment for CNS germ cell tumours: consensus recommendations from the European Society for Paediatric Oncology Brain Tumour Group and North American Children's Oncology Group. Lancet Oncol. 2022;23(5):e218–e228.
18.
EisenhauerEATherassePBogaertsJ, et al.New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247.
19.
YamaguchiSOkamotoMIshiY, et al.Long-term consequences of residual lesions after chemoradiotherapy in patients with germinoma at onset. J Neurosurg Pediatr. 2022;30(5):517–524.
20.
Abu ArjaMHBouffetEFinlayJLAbdelBakiMS. Critical review of the management of primary central nervous nongerminomatous germ cell tumors. Pediatr Blood Cancer. 2019;66(6):e27658.
21.
HongKTHanJWFujiH, et al.Outcomes of intracranial non-germinomatous germ cell tumors: a retrospective Asian multinational study on treatment strategies and prognostic factors. J Neurooncol. 2022;160(1):41–53.
22.
QaddoumiISaneMLiS, et al.Diagnostic utility and correlation of tumor markers in the serum and cerebrospinal fluid of children with intracranial germ cell tumors. Childs Nerv Syst. 2012;28(7):1017–1024.
23.
DiSaiaPJSaltzAKaganARMorrowCP. Chemotherapeutic retroconversion of immature teratoma of the ovary. Obstet Gynecol. 1977;49(3):346–350.
24.
OgiwaraHKiyotaniCTerashimaKMorotaN. Second-look surgery for intracranial germ cell tumors. Neurosurgery. 2015;76(6):658–61; discussion 61-2.
25.
WeinerHLLichtenbaumRAWisoffJH, et al.Delayed surgical resection of central nervous system germ cell tumors. Neurosurgery. 2002;50(4):727–33; discussion 33-4.
26.
MurrayMJBartelsUNishikawaRFangusaroJMatsutaniMNicholsonJC. Consensus on the management of intracranial germ-cell tumours. Lancet Oncol. 2015;16(9):e470–e4e7.
27.
MokhtechMRotondoRLBradleyJA, et al.Early outcomes and patterns of failure following proton therapy for nonmetastatic intracranial nongerminomatous germ cell tumors. Pediatr Blood Cancer. 2018;65(6):e26997.
28.
FrappazDDhallGMurrayMJ, et al.EANO, SNO and Euracan consensus review on the current management and future development of intracranial germ cell tumors in adolescents and young adults. Neuro Oncol. 2022;24(4):516–527.
